National Research Institute of Tuberculosis and Lung Disease, Iran Report issue

Government Phase 4
Founded: Tehran Iran (Islamic Republic of)

Organization Overview

First Clinical Trial
2007
NCT00537875
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

National Research Institute of Tuberculosis and Lung Disease, Iran

Active Ingredients

Drugs in Phase 4 Trials (1)

prednisone (meticorten) (1 trial)

Drugs in Other Trials (3)

acetylcysteine (mucomyst) (1 trial)

ginger (1 trial)

magnesium sulfate (Tis-U-Sol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Constriction, Pathologic (Phase 4)

Tracheal Stenosis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 4